BROMFENAC solution/ drops

Bromfenac by

Drug Labeling and Warnings

Bromfenac by is a Prescription medication manufactured, distributed, or labeled by Amneal Pharmaceuticals NY LLC, Amneal Pharmaceuticals Private Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Bromfenac ophthalmic solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosage

    Apply one drop to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.

    2.2 Use with Other Topical Ophthalmic Medications

    Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

  • 3 DOSAGE FORMS AND STRENGTHS

    Ophthalmic solution: bromfenac 0.07%.

  • 4 CONTRAINDICATIONS

    None.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Sulfite Allergic Reactions

    Bromfenac ophthalmic solution contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

    5.2 Slow or Delayed Healing

    All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

    5.3 Potential for Cross-Sensitivity

    There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

    5.4 Increased Bleeding Time

    With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

    It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

    5.5 Keratitis and Corneal Reactions

    Use of topical NSAIDs, including bromfenac, may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health.

    Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

    Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

    5.6 Risk of Contamination

    Do not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the contents. Replace the bottle cap after using.

    5.7 Contact Lens Wear

    Bromfenac ophthalmic solution should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The most commonly reported adverse reactions following use of bromfenac following cataract surgery include: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. These reactions were reported in 3% to 8% of patients.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no available data on bromfenac use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

    The systemic exposure to bromfenac following topical ocular administration is low [see Clinical Pharmacology (12.3)]. Consequently, the systemic exposure of a pregnant woman to bromfenac is expected to be minimal following topical ocular administration.

    However, because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac during late pregnancy should be avoided.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    Clinical Considerations

    Premature closure of the ductus arteriosus in the fetus has occurred with third trimester use of oral and injectable NSAIDs. Measurable maternal and fetal plasma drug levels are available with oral and injectable routes of NSAID administration. The maternal plasma level of bromfenac following ocular administration is unknown [see Clinical Pharmacology (12.3)].

    Data

    Animal Data

    Embryo-fetal lethality and maternal toxicity were produced in rats and rabbits treated with bromfenac during the period of organogenesis at oral doses up to 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. These doses corresponded to a Cmax 90- and 150- times the predicted Cmax at the recommended human ophthalmic dose (RHOD), respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human Cmax at the RHOD), and caused dystocia, increased neonatal mortality, and reduced postnatal growth at 0.9 mg/kg/day (90 times the predicted human Cmax at the RHOD).

    8.2 Lactation

    There are no data on the presence of bromfenac in human milk, the effects on the breastfed infant, or the effects on milk production.

    The systemic exposure of a breastfeeding woman to bromfenac is expected to be minimal following topical ocular administration, however, the possibility of harm to the breastfed infant cannot be ruled out.

    The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for bromfenac, and any potential adverse effects on the breastfed infant from bromfenac or from the underlying maternal conditions.

    8.4 Pediatric Use

    The safety and effectiveness of bromfenac have not been established in pediatric patients.

    8.5 Geriatric Use

    No overall differences in safety or effectiveness of bromfenac have been observed between patients 70 years of age and older and younger adult patients.

  • 11 DESCRIPTION

    Bromfenac ophthalmic solution, 0.07% is a sterile, nonsteroidal anti-inflammatory drug (NSAID) for topical ophthalmic use. Each mL of bromfenac ophthalmic solution contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid). The USAN name for bromfenac sodium sesquihydrate is bromfenac sodium. Bromfenac sodium is designated chemically as sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, with a molecular formula of C15H11BrNNaO31.5 H2O. The chemical structure for bromfenac sodium sesquihydrate is:

    1

    Bromfenac sodium is a bright orange to yellow powder. It is freely soluble in water, soluble in methanol and very slightly soluble in chloroform, dilute acid and diluted base. The molecular weight of bromfenac sodium is 383.17 g/mol. Bromfenac ophthalmic solution is a clear, yellow solution and supplied as a sterile aqueous 0.07% solution, with a pH of 7.8. The osmolality of bromfenac ophthalmic solution is approximately 300 mOsmol/kg.

    Each mL of bromfenac ophthalmic solution contains:

    Active: Each mL contains bromfenac sodium sesquihydrate 0.0805%, which is equivalent to bromfenac free acid 0.07%.

    Inactives: boric acid, edetate disodium, povidone, sodium borate, sodium sulfite, tyloxapol, sodium hydroxide to adjust pH, and water for injection, USP.

    Preservative: benzalkonium chloride 0.005%.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

    12.3 Pharmacokinetics

    The plasma concentration of bromfenac following ocular administration of bromfenac ophthalmic solution 0.07% in humans is unknown. Based on the maximum proposed dose of one drop to each eye (0.035 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from RHOD assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively, revealed no significant increases in tumor incidence.

    Mutagenesis

    Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.

    Impairment of Fertility

    Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively).

  • 14 CLINICAL STUDIES

    14.1 Ocular Inflammation and Pain

    Bromfenac 0.07% QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery. Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8 and 15 post-surgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by Day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table.

    Proportion of Subjects with Cleared Ocular Inflammation (0 cell and no flare)

    Study

    Visit

    Bromfenac 0.07%

    Vehicle

    Difference (%) (Asymptotic 95% CI)

    Study 1

    At Day 8

    27/112 (24.1%)

    7/108 (6.5%)

    17.6 (8.4, 26.8)

    At Day 15

    51/112 (45.5%)

    14/108 (13.0%)

    32.5 (21.4, 43.8)

    Study 2

    At Day 8

    33/110 (30.0%)

    14/110 (12.7%)

    17.3 (6.7, 27.9)

    At Day 15

    50/110 (45.5%)

    30/110 (27.3%)

    18.2 (5.7, 30.7)

    Proportion of Subjects Who Were Pain Free

    Study

    Visit

    Bromfenac 0.07%

    Vehicle

    Difference (%) (Asymptotic 95% CI)

    Study 1

    At Day 1

    91/112 (81.3%)

    47/108 (43.5%)

    37.7 (25.9, 49.6)

    Study 2

    At Day 1

    84/110 (76.4%)

    61/110 (55.5%)

    20.9 (8.7, 33.1)
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Bromfenac ophthalmic solution is a clear, yellow solution and supplied in white LDPE opaque bottle with a LDPE white opaque nozzle and HDPE grey cap. Each mL contains bromfenac sodium sesquihydrate 0.0805% equivalent to bromfenac free acid 0.07%. It is available as follows:

    3 mL in 5 mL Container:                                NDC: 60219-1526-3

    Storage

    Store at 15° to 25°C (59° to 77°F). After opening, bromfenac ophthalmic solution can be used until the expiration date on the bottle.

  • 17 PATIENT COUNSELING INFORMATION

    Slow or Delayed Healing

    Advise patients of the possibility that slow or delayed healing may occur while using NSAIDs.

    Risk of Contamination

    Advise patients to not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the

    contents. Advise patients to replace bottle cap after using.

    Contact Lens Wear

    Advise patients to remove contact lenses prior to instillation of bromfenac ophthalmic solution. The preservative in bromfenac ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution.

    Use with Other Topical Ophthalmic Medications

    Advise patients that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.

    Manufactured by:

    Amneal Pharmaceuticals Pvt. Ltd.

    Ahmedabad 382213, INDIA

    Distributed by:

    Amneal Pharmaceuticals LLC

    Bridgewater, NJ 08807

    Rev. 03-2025-01

  • PRINCIPAL DISPLAY PANEL

    NDC: 60219-1526-3

    Bromfenac ophthalmic solution, 0.07% (3 mL)

    Rx only

    Amneal Pharmaceuticals LLC

    lbl

    ctn
  • INGREDIENTS AND APPEARANCE
    BROMFENAC 
    bromfenac solution/ drops
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 60219-1526
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BROMFENAC SODIUM (UNII: 8ECV571Y37) (BROMFENAC - UNII:864P0921DW) BROMFENAC0.7 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7) 0.05 mg  in 1 mL
    BORIC ACID (UNII: R57ZHV85D4)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    POVIDONE (UNII: FZ989GH94E)  
    SODIUM BORATE (UNII: 91MBZ8H3QO)  
    SODIUM SULFITE (UNII: VTK01UQK3G)  
    TYLOXAPOL (UNII: Y27PUL9H56)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 60219-1526-31 in 1 CARTON07/31/2024
    13 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21096207/31/2024
    Labeler - Amneal Pharmaceuticals NY LLC (123797875)
    Establishment
    NameAddressID/FEIBusiness Operations
    Amneal Pharmaceuticals Private Limited860156658analysis(60219-1526) , manufacture(60219-1526) , pack(60219-1526) , sterilize(60219-1526)
    • © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.